NICE recommends Boehringer’s Pradaxa to treat and prevent recurrence of DVT and PE
In the UK, venous thrombosis or blood clotting is a major cause of death and for those patients that survive PE and DVT, there can be long term
In the UK, venous thrombosis or blood clotting is a major cause of death and for those patients that survive PE and DVT, there can be long term
The approval was based on demonstration of improved progression-free survival (PFS) in a 96-week Phase III trial called CLARINET. The multi-center, international, randomized, double-blind, placebo-controlled trial enrolled a
Backed by funding of €15.1m from the European Commission (EC), the new consortium includes GSK and research partners from University of Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne
Signifor LAR is a somatostatin analog (SSA) administered intramuscularly once-monthly, which exerts its pharmacological activity through binding to somatostatin receptors (SSTRs). Novartis Oncology president Bruno Strigini said: "The
ESUS occurs when a blood clot from somewhere in the body blocks a blood vessel in the brain and the source of this blood clot is unknown. In
The submission is based on results from Phase III trial, which evaluated the safety, tolerability and efficacy of Xtampza ER compared with placebo in opioid-experienced and opioid-naïve subjects
The trial will be conducted with ADXS11-001 alone or in combination with MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736 The combination drug is indicated to treat advanced, recurrent
The deal will see the two parties establish a global strategic collaboration to jointly develop next generation immunotherapies to treat cancer and auto-immune diseases. NantWorks, through a subsidiary,
NEOD001 targets the circulating soluble amyloid and deposited insoluble amyloid that accumulates in both the AL and AA forms of amyloidosis. According to the company, this is the
The new regulatory submission follows the Japanese approval of dolutegravir as Tivicay tablets 50mg in March 2014. In the approved regions, the single-pill dolutegravir-based regimen is called as